Jin Sun Lee1, Susan E Yost1, Yuan Yuan1. 1. Department of Medical Oncology & Molecular Therapeutics, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, United States.
Abstract
BACKGROUND: Triple negative breast cancer (TNBC) has poor prognosis without targetable mutations. The combination of lenvatinib and pembrolizumab has shown clinical activity in different types of solid tumors. CASE PRESENTATION: We report a case of one patient with metastatic TNBC who has been heavily pretreated. The patient had been treated with multiple lines (≥ 8 lines) of chemotherapy without durable clinical responses. Her tumor regressed significantly under the combination of lenvatinib and immune checkpoint inhibitor, and remains stable for 10 months. CONCLUSIONS: The combination of lenvatinib and immune checkpoint inhibitor may have significant clinical activity in selective patients with heavily pretreated metastatic TNBC.
BACKGROUND: Triple negative breast cancer (TNBC) has poor prognosis without targetable mutations. The combination of lenvatinib and pembrolizumab has shown clinical activity in different types of solid tumors. CASE PRESENTATION: We report a case of one patient with metastatic TNBC who has been heavily pretreated. The patient had been treated with multiple lines (≥ 8 lines) of chemotherapy without durable clinical responses. Her tumor regressed significantly under the combination of lenvatinib and immune checkpoint inhibitor, and remains stable for 10 months. CONCLUSIONS: The combination of lenvatinib and immune checkpoint inhibitor may have significant clinical activity in selective patients with heavily pretreated metastatic TNBC.
Authors: Vicky Makker; Drew Rasco; Nicholas J Vogelzang; Marcia S Brose; Allen L Cohn; James Mier; Christopher Di Simone; David M Hyman; Daniel E Stepan; Corina E Dutcus; Emmett V Schmidt; Matthew Guo; Pallavi Sachdev; Robert Shumaker; Carol Aghajanian; Matthew Taylor Journal: Lancet Oncol Date: 2019-03-25 Impact factor: 41.316
Authors: Kevin C Barry; Joy Hsu; Miranda L Broz; Francisco J Cueto; Mikhail Binnewies; Alexis J Combes; Amanda E Nelson; Kimberly Loo; Raj Kumar; Michael D Rosenblum; Michael D Alvarado; Denise M Wolf; Dusan Bogunovic; Nina Bhardwaj; Adil I Daud; Patrick K Ha; William R Ryan; Joshua L Pollack; Bushra Samad; Saurabh Asthana; Vincent Chan; Matthew F Krummel Journal: Nat Med Date: 2018-06-25 Impact factor: 53.440
Authors: S Adams; P Schmid; H S Rugo; E P Winer; D Loirat; A Awada; D W Cescon; H Iwata; M Campone; R Nanda; R Hui; G Curigliano; D Toppmeyer; J O'Shaughnessy; S Loi; S Paluch-Shimon; A R Tan; D Card; J Zhao; V Karantza; J Cortés Journal: Ann Oncol Date: 2019-03-01 Impact factor: 32.976
Authors: Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: N Engl J Med Date: 2018-10-20 Impact factor: 91.245
Authors: Vicky Makker; Matthew H Taylor; Carol Aghajanian; Ana Oaknin; James Mier; Allen L Cohn; Margarita Romeo; Raquel Bratos; Marcia S Brose; Christopher DiSimone; Mark Messing; Daniel E Stepan; Corina E Dutcus; Jane Wu; Emmett V Schmidt; Robert Orlowski; Pallavi Sachdev; Robert Shumaker; Antonio Casado Herraez Journal: J Clin Oncol Date: 2020-03-13 Impact factor: 44.544
Authors: Rachael M Zemek; Wee Loong Chin; Anna K Nowak; Michael J Millward; Richard A Lake; W Joost Lesterhuis Journal: Front Immunol Date: 2020-02-18 Impact factor: 7.561
Authors: Khuloud Bajbouj; Rizwan Qaisar; Mohammed A Alshura; Zeinab Ibrahim; Mohamad B Alebaji; Amenah W Al Ani; Hanadi M Janajrah; Mariah M Bilalaga; Abdelrahman I Omara; Rebal S Abou Assaleh; Maha M Saber-Ayad; Adel B Elmoselhi Journal: Int J Mol Sci Date: 2022-04-16 Impact factor: 6.208